Global Microbiome Drugs Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Microbiome Drugs Market
Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

The global Microbiome Drugs market size is projected to reach US$ 1815.7 million by 2028, from US$ 222 million in 2021, at a CAGR of 34.6% during 2022-2028.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Microbiome Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Microbiome Drugs market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Microbiome Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Microbiome Drugs market.

Impact of Covid-19 Outbreak

This section of the report has explored the overall status of the Covid scenario and has offered valuable insights into the changes in supply chain disruption, fluctuations in demand, etc. The analysts have also focused on the key measures that the companies are opting to withstand the harsh scenario.

Segmental Analysis

The report has been segmented into product and application segments. The researchers have documented all the products present today in the Microbiome Drugs market. They have also shed light on the new product innovations and launches by the key players. In the segmental analysis, the analysts have provided revenue forecast figures based on type and application for the period 2017-2028. They have also discussed about the growth rate and potential of each segment for the period 2017-2028.

Microbiome Drugs Breakdown Data by Type

Oral Dosage Form

Enteric Capsules

Microbiome Drugs Breakdown Data by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Competitive Landscape

This segment focuses on the key players operating in the industry. It underlines all the current and future activities by the prominent manufacturers. By understanding various initiatives being taken up by different players, readers will gain the ability to settle on correct business choices. The authors of the report have provided accurate revenue figures of the companies for the period 2017-2022. The clients are sure to gain the upper hand once they get hold of this report. Key players studied in the research report include:

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

TABLE OF CONTENT

1 Report Business Overview
1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Microbiome Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Oral Dosage Form

1.2.3 Enteric Capsules

1.3 Market by Symptom

1.3.1 Global Microbiome Drugs Market Size Growth Rate by Symptom, 2017 VS 2021 VS 2028

1.3.2 Gastrointestinal Disorders

1.3.3 Autoimmune Disorders

1.3.4 Diabetes

1.3.5 Cancer

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Microbiome Drugs Market Perspective (2017-2028)

2.2 Microbiome Drugs Growth Trends by Region

2.2.1 Microbiome Drugs Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Microbiome Drugs Historic Market Size by Region (2017-2022)

2.2.3 Microbiome Drugs Forecasted Market Size by Region (2023-2028)

2.3 Microbiome Drugs Market Dynamics

2.3.1 Microbiome Drugs Industry Trends

2.3.2 Microbiome Drugs Market Drivers

2.3.3 Microbiome Drugs Market Challenges

2.3.4 Microbiome Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Microbiome Drugs Players by Revenue

3.1.1 Global Top Microbiome Drugs Players by Revenue (2017-2022)

3.1.2 Global Microbiome Drugs Revenue Market Share by Players (2017-2022)

3.2 Global Microbiome Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Microbiome Drugs Revenue

3.4 Global Microbiome Drugs Market Concentration Ratio

3.4.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Microbiome Drugs Revenue in 2021

3.5 Microbiome Drugs Key Players Head office and Area Served

3.6 Key Players Microbiome Drugs Product Solution and Service

3.7 Date of Enter into Microbiome Drugs Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Microbiome Drugs Breakdown Data by Type

4.1 Global Microbiome Drugs Historic Market Size by Type (2017-2022)

4.2 Global Microbiome Drugs Forecasted Market Size by Type (2023-2028)

5 Microbiome Drugs Breakdown Data by Symptom

5.1 Global Microbiome Drugs Historic Market Size by Symptom (2017-2022)

5.2 Global Microbiome Drugs Forecasted Market Size by Symptom (2023-2028)

6 North America

6.1 North America Microbiome Drugs Market Size (2017-2028)

6.2 North America Microbiome Drugs Market Size by Type

6.2.1 North America Microbiome Drugs Market Size by Type (2017-2022)

6.2.2 North America Microbiome Drugs Market Size by Type (2023-2028)

6.2.3 North America Microbiome Drugs Market Share by Type (2017-2028)

6.3 North America Microbiome Drugs Market Size by Symptom

6.3.1 North America Microbiome Drugs Market Size by Symptom (2017-2022)

6.3.2 North America Microbiome Drugs Market Size by Symptom (2023-2028)

6.3.3 North America Microbiome Drugs Market Share by Symptom (2017-2028)

6.4 North America Microbiome Drugs Market Size by Country

6.4.1 North America Microbiome Drugs Market Size by Country (2017-2022)

6.4.2 North America Microbiome Drugs Market Size by Country (2023-2028)

6.4.3 United States

6.4.4 Canada

7 Europe

7.1 Europe Microbiome Drugs Market Size (2017-2028)

7.2 Europe Microbiome Drugs Market Size by Type

7.2.1 Europe Microbiome Drugs Market Size by Type (2017-2022)

7.2.2 Europe Microbiome Drugs Market Size by Type (2023-2028)

7.2.3 Europe Microbiome Drugs Market Share by Type (2017-2028)

7.3 Europe Microbiome Drugs Market Size by Symptom

7.3.1 Europe Microbiome Drugs Market Size by Symptom (2017-2022)

7.3.2 Europe Microbiome Drugs Market Size by Symptom (2023-2028)

7.3.3 Europe Microbiome Drugs Market Share by Symptom (2017-2028)

7.4 Europe Microbiome Drugs Market Size by Country

7.4.1 Europe Microbiome Drugs Market Size by Country (2017-2022)

7.4.2 Europe Microbiome Drugs Market Size by Country (2023-2028)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Microbiome Drugs Market Size (2017-2028)

8.2 Asia-Pacific Microbiome Drugs Market Size by Type

8.2.1 Asia-Pacific Microbiome Drugs Market Size by Type (2017-2022)

8.2.2 Asia-Pacific Microbiome Drugs Market Size by Type (2023-2028)

8.2.3 Asia-Pacific Microbiome Drugs Market Share by Type (2017-2028)

8.3 Asia-Pacific Microbiome Drugs Market Size by Symptom

8.3.1 Asia-Pacific Microbiome Drugs Market Size by Symptom (2017-2022)

8.3.2 Asia-Pacific Microbiome Drugs Market Size by Symptom (2023-2028)

8.3.3 Asia-Pacific Microbiome Drugs Market Share by Symptom (2017-2028)

8.4 Asia-Pacific Microbiome Drugs Market Size by Region

8.4.1 Asia-Pacific Microbiome Drugs Market Size by Region (2017-2022)

8.4.2 Asia-Pacific Microbiome Drugs Market Size by Region (2023-2028)

8.4.3 China

8.4.4 Japan

8.4.5 South Korea

8.4.6 Southeast Asia

8.4.7 India

8.4.8 Australia

9 Latin America

9.1 Latin America Microbiome Drugs Market Size (2017-2028)

9.2 Latin America Microbiome Drugs Market Size by Type

9.2.1 Latin America Microbiome Drugs Market Size by Type (2017-2022)

9.2.2 Latin America Microbiome Drugs Market Size by Type (2023-2028)

9.2.3 Latin America Microbiome Drugs Market Share by Type (2017-2028)

9.3 Latin America Microbiome Drugs Market Size by Symptom

9.3.1 Latin America Microbiome Drugs Market Size by Symptom (2017-2022)

9.3.2 Latin America Microbiome Drugs Market Size by Symptom (2023-2028)

9.3.3 Latin America Microbiome Drugs Market Share by Symptom (2017-2028)

9.4 Latin America Microbiome Drugs Market Size by Country

9.4.1 Latin America Microbiome Drugs Market Size by Country (2017-2022)

9.4.2 Latin America Microbiome Drugs Market Size by Country (2023-2028)

9.4.3 Mexico

9.4.4 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Microbiome Drugs Market Size (2017-2028)

10.2 Middle East & Africa Microbiome Drugs Market Size by Type

10.2.1 Middle East & Africa Microbiome Drugs Market Size by Type (2017-2022)

10.2.2 Middle East & Africa Microbiome Drugs Market Size by Type (2023-2028)

10.2.3 Middle East & Africa Microbiome Drugs Market Share by Type (2017-2028)

10.3 Middle East & Africa Microbiome Drugs Market Size by Symptom

10.3.1 Middle East & Africa Microbiome Drugs Market Size by Symptom (2017-2022)

10.3.2 Middle East & Africa Microbiome Drugs Market Size by Symptom (2023-2028)

10.3.3 Middle East & Africa Microbiome Drugs Market Share by Symptom (2017-2028)

10.4 Middle East & Africa Microbiome Drugs Market Size by Country

10.4.1 Middle East & Africa Microbiome Drugs Market Size by Country (2017-2022)

10.4.2 Middle East & Africa Microbiome Drugs Market Size by Country (2023-2028)

10.4.3 Turkey

10.4.4 Saudi Arabia

10.4.5 UAE

11 Key Players Profiles

11.1 Seres Therapeutics

11.1.1 Seres Therapeutics Company Details

11.1.2 Seres Therapeutics Business Overview

11.1.3 Seres Therapeutics Microbiome Drugs Introduction

11.1.4 Seres Therapeutics Revenue in Microbiome Drugs Business (2017-2022)

11.1.5 Seres Therapeutics Recent Developments

11.2 Assembly Biosciences

11.2.1 Assembly Biosciences Company Details

11.2.2 Assembly Biosciences Business Overview

11.2.3 Assembly Biosciences Microbiome Drugs Introduction

11.2.4 Assembly Biosciences Revenue in Microbiome Drugs Business (2017-2022)

11.2.5 Assembly Biosciences Recent Developments

11.3 Synthetic Biologics

11.3.1 Synthetic Biologics Company Details

11.3.2 Synthetic Biologics Business Overview

11.3.3 Synthetic Biologics Microbiome Drugs Introduction

11.3.4 Synthetic Biologics Revenue in Microbiome Drugs Business (2017-2022)

11.3.5 Synthetic Biologics Recent Developments

11.4 Interxon

11.4.1 Interxon Company Details

11.4.2 Interxon Business Overview

11.4.3 Interxon Microbiome Drugs Introduction

11.4.4 Interxon Revenue in Microbiome Drugs Business (2017-2022)

11.4.5 Interxon Recent Developments

11.5 PureTech

11.5.1 PureTech Company Details

11.5.2 PureTech Business Overview

11.5.3 PureTech Microbiome Drugs Introduction

11.5.4 PureTech Revenue in Microbiome Drugs Business (2017-2022)

11.5.5 PureTech Recent Developments

11.6 Synlogic

11.6.1 Synlogic Company Details

11.6.2 Synlogic Business Overview

11.6.3 Synlogic Microbiome Drugs Introduction

11.6.4 Synlogic Revenue in Microbiome Drugs Business (2017-2022)

11.6.5 Synlogic Recent Developments

11.7 Enterome BioScience

11.7.1 Enterome BioScience Company Details

11.7.2 Enterome BioScience Business Overview

11.7.3 Enterome BioScience Microbiome Drugs Introduction

11.7.4 Enterome BioScience Revenue in Microbiome Drugs Business (2017-2022)

11.7.5 Enterome BioScience Recent Developments

11.8 4D Pharma

11.8.1 4D Pharma Company Details

11.8.2 4D Pharma Business Overview

11.8.3 4D Pharma Microbiome Drugs Introduction

11.8.4 4D Pharma Revenue in Microbiome Drugs Business (2017-2022)

11.8.5 4D Pharma Recent Developments

11.9 Second Genome

11.9.1 Second Genome Company Details

11.9.2 Second Genome Business Overview

11.9.3 Second Genome Microbiome Drugs Introduction

11.9.4 Second Genome Revenue in Microbiome Drugs Business (2017-2022)

11.9.5 Second Genome Recent Developments

11.10 AOBiome

11.10.1 AOBiome Company Details

11.10.2 AOBiome Business Overview

11.10.3 AOBiome Microbiome Drugs Introduction

11.10.4 AOBiome Revenue in Microbiome Drugs Business (2017-2022)

11.10.5 AOBiome Recent Developments

11.11 Rebiotix

11.11.1 Rebiotix Company Details

11.11.2 Rebiotix Business Overview

11.11.3 Rebiotix Microbiome Drugs Introduction

11.11.4 Rebiotix Revenue in Microbiome Drugs Business (2017-2022)

11.11.5 Rebiotix Recent Developments

11.12 Metabiomics

11.12.1 Metabiomics Company Details

11.12.2 Metabiomics Business Overview

11.12.3 Metabiomics Microbiome Drugs Introduction

11.12.4 Metabiomics Revenue in Microbiome Drugs Business (2017-2022)

11.12.5 Metabiomics Recent Developments

11.13 Ritter Pharmaceuticals

11.13.1 Ritter Pharmaceuticals Company Details

11.13.2 Ritter Pharmaceuticals Business Overview

11.13.3 Ritter Pharmaceuticals Microbiome Drugs Introduction

11.13.4 Ritter Pharmaceuticals Revenue in Microbiome Drugs Business (2017-2022)

11.13.5 Ritter Pharmaceuticals Recent Developments

11.14 Symberix

11.14.1 Symberix Company Details

11.14.2 Symberix Business Overview

11.14.3 Symberix Microbiome Drugs Introduction

11.14.4 Symberix Revenue in Microbiome Drugs Business (2017-2022)

11.14.5 Symberix Recent Developments

11.15 OpenBiome

11.15.1 OpenBiome Company Details

11.15.2 OpenBiome Business Overview

11.15.3 OpenBiome Microbiome Drugs Introduction

11.15.4 OpenBiome Revenue in Microbiome Drugs Business (2017-2022)

11.15.5 OpenBiome Recent Developments

11.16 Azitra

11.16.1 Azitra Company Details

11.16.2 Azitra Business Overview

11.16.3 Azitra Microbiome Drugs Introduction

11.16.4 Azitra Revenue in Microbiome Drugs Business (2017-2022)

11.16.5 Azitra Recent Developments

11.17 Osel

11.17.1 Osel Company Details

11.17.2 Osel Business Overview

11.17.3 Osel Microbiome Drugs Introduction

11.17.4 Osel Revenue in Microbiome Drugs Business (2017-2022)

11.17.5 Osel Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Author Details

13.3 Disclaimer

Choose License Type

Checkout Inquiry Sample